A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma

A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma

Oral squamous cell carcinoma (OSCC) represents ~90% of all oral cancers, being the eighth most common cancer in men. The overall 5-year survival rate is only 39% for metastatic cancers, and currently used chemotherapeutics can cause important side effects. Thus, there is an urgency in developing new...

Full description

Bibliographic Details
Main Authors:	Guilherme Freimann Wermelinger, Lucas Rubini, Anna Carolina Carvalho da Fonseca, Gabriel Ouverney, Rafael P. R. F. de Oliveira, Acácio S. de Souza, Luana S. M. Forezi, Gabriel Limaverde-Sousa, Sergio Pinheiro, Bruno Kaufmann Robbs
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Biomedicines
Subjects:	chalcone 1,2,3-triazole MDM2 p53 antitumor oral squamous cell carcinoma
Online Access:	https://www.mdpi.com/2227-9059/11/6/1711

Similar Items

Structure–Activity Relationship Studies of Chalcones and Diarylpentanoids with Antitumor Activity: Potency and Selectivity Optimization
by: Joana Moreira, et al.
Published: (2023-09-01)

Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness
by: Joana Moreira, et al.
Published: (2021-06-01)

Synthesis of newer substituted chalcone linked 1,2,3-triazole analogs and evaluation of their cytotoxic activities
by: Raghavender Matta, et al.
Published: (2022-10-01)

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53
by: Zhaofeng Liu, et al.
Published: (2024-02-01)

Eugenol derivatives containing 1,2,3-triazole-chalcone hybrids for shikimate kinase inhibition
by: Bayu Ardiansah, et al.
Published: (2024-03-01)

Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signalling pathway
by: Su Qing, et al.
Published: (2022-09-01)

Design, Synthesis and Structure-Activity Relationships of Novel Chalcone-1,2,3-triazole-azole Derivates as Antiproliferative Agents
by: Sai-Yang Zhang, et al.
Published: (2016-05-01)

Synthesis, characterization, cytotoxic evaluation, and molecular docking studies of novel 1,2,3-triazole-based chalcones for potential anticancer applications
by: Venkateswarlu Banoji, et al.
Published: (2024-01-01)

Recent advances in chalcone-triazole hybrids as potential pharmacological agents
by: Akanksha Bhukal, et al.
Published: (2023-12-01)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
by: Venkatesh, Byrappa, et al.
Published: (2016)

Synthesis, Characterization and Antibacterial Activity of Some New of Novel 1,2,3-Triazole-Chalcone Derivatives from N-Acetyl-5H-Dibenzo [b,f] Azepine-5-Carboxamide
by: Ruaa Wassim Adam, et al.
Published: (2019-06-01)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01)

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
by: Xiang Li, et al.
Published: (2021-09-01)

Design, synthesis and in silico docking techniques of new 1,2,3-triazolylpyrrolidines bearing chalcone derivatives: Discovery of potent antitubercular agents
by: Veera Sankara Pavan Kumar Gudapati, et al.
Published: (2024-01-01)

Step-by-step synthetic route to access eugenol-1,2,3-triazole-chalcone hybrid
by: Atta Ullah, et al.
Published: (2024-12-01)

CuAAC-Based Synthesis, Copper-Catalyzed Aldehyde-Forming Hydrolytic Fission and Antiproliferative Evaluation of Novel Ferrocenoylamino-Substituted Triazole-Tethered Quinine–Chalcone Hybrids
by: António Dembo, et al.
Published: (2024-01-01)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
by: Johanna Huun, et al.
Published: (2017-04-01)

Synthesis of novel pyrazoline based bis (1,2,3-triazole) scaffolds via click chemistry
by: Kiran Kothuri, et al.
Published: (2017-01-01)

Discovery of a Series of Theophylline Derivatives Containing 1,2,3-Triazole for Treatment of Non-Small Cell Lung Cancer
by: Jiahui Ye, et al.
Published: (2021-10-01)

MDM2 inhibitors in cancer immunotherapy: Current status and perspective
by: Qinru Zeng, et al.
Published: (2024-11-01)

Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation
by: Rati Lama, et al.
Published: (2024-12-01)

Discovery of a New Chalcone-Trimethoxycinnamide Hybrid with Antimitotic Effect: Design, Synthesis, and Structure—Activity Relationship Studies
by: Joana Moreira, et al.
Published: (2023-06-01)

p53 and MDM2 protein expression in actinic cheilitis
by: Maria da Conceição Andrade de Freitas, et al.
Published: (2008-12-01)

The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53–MDM2 Modulation
by: Adel S. Girgis, et al.
Published: (2025-02-01)

Microwave-assisted synthesis of new pyrazole derivatives bearing 1,2,3-triazole scaffold as potential antimicrobial agents
by: Ashok Dongamanti, et al.
Published: (2017-01-01)

Modulating the p53-MDM2 pathway
by: Iman Ramli, et al.
Published: (2024-11-01)

Design, synthesis and antitumour activity evaluation of novel dolutegravir derivatives
by: Xi-Xi Hou, et al.
Published: (2023-08-01)

Correlation between p53 and Mdm2 expression with histopathological parameters in cattle squamous cell carcinomas
by: Waseem Al-Jameel, et al.
Published: (2022-01-01)

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma
by: Tao Chen, et al.
Published: (2021-08-01)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
by: Haohao Zhu, et al.
Published: (2022-07-01)

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
by: Ali M. Alaseem
Published: (2023-10-01)

Controlling the Mdm2-Mdmx-p53 Circuit
by: David L. Waning, et al.
Published: (2010-05-01)

High Expression of MDM2 and the p53 Protein is Predictive Biomarkers for Poor Prognosis of Oesophageal Squamous Cell Carcinoma
by: Ye J, et al.
Published: (2021-03-01)

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
by: Hui Qin Wang, et al.
Published: (2017-04-01)

miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2
by: Cai Y, et al.
Published: (2019-11-01)

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
by: Lucia Haronikova, et al.
Published: (2021-12-01)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
by: Helei Hou, et al.
Published: (2019-08-01)

Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
by: Viktoria K. Ilic, et al.
Published: (2022-04-01)

Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
by: Xin Tian, et al.
Published: (2016-10-01)

Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
by: Peng Deng, et al.
Published: (2022-01-01)